Diaceutics’ (DXRX) “Buy” Rating Reiterated at Canaccord Genuity Group

Diaceutics (LON:DXRX)‘s stock had its “buy” rating reiterated by stock analysts at Canaccord Genuity Group in a research report issued on Tuesday, September 22nd, Digital Look reports. They currently have a GBX 215 price objective on the stock. Canaccord Genuity Group’s target price suggests a potential upside of 11.98% from the stock’s previous close.

Diaceutics Price Performance

Shares of LON DXRX traded up GBX 0.50 during mid-day trading on Tuesday, hitting GBX 192. 336,266 shares of the company’s stock traded hands, compared to its average volume of 209,694. The company’s 50-day moving average is GBX 150.39 and its two-hundred day moving average is GBX 152.16. The company has a debt-to-equity ratio of 5.40, a current ratio of 2.55 and a quick ratio of 9.92. The company has a market capitalization of £162.93 million, a P/E ratio of 1,745.45 and a beta of 0.88. Diaceutics has a 1 year low of GBX 125 and a 1 year high of GBX 197.

Diaceutics (LON:DXRX) last released its quarterly earnings results on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a negative return on equity of 0.68% and a negative net margin of 0.66%. On average, equities analysts anticipate that Diaceutics will post 1.0107919 EPS for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.